These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26022561)

  • 21. Recent progress in adjuvant discovery for peptide-based subunit vaccines.
    Azmi F; Ahmad Fuaad AA; Skwarczynski M; Toth I
    Hum Vaccin Immunother; 2014; 10(3):778-96. PubMed ID: 24300669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
    Banday AH; Jeelani S; Hruby VJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic identification of small molecule adjuvants.
    Flower DR
    Expert Opin Drug Discov; 2012 Sep; 7(9):807-17. PubMed ID: 22724523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designing and building the next generation of improved vaccine adjuvants.
    Brito LA; O'Hagan DT
    J Control Release; 2014 Sep; 190():563-79. PubMed ID: 24998942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomaterials as vaccine adjuvants.
    Jones KS
    Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypothesis driven development of new adjuvants: short peptides as immunomodulators.
    Dong JC; Kobinger GP
    Hum Vaccin Immunother; 2013 Apr; 9(4):808-11. PubMed ID: 23563510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New horizons in adjuvants for vaccine development.
    Reed SG; Bertholet S; Coler RN; Friede M
    Trends Immunol; 2009 Jan; 30(1):23-32. PubMed ID: 19059004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine adjuvant technology: from mechanistic concepts to practical applications.
    Degen WG; Jansen T; Schijns VE
    Expert Rev Vaccines; 2003 Apr; 2(2):327-35. PubMed ID: 12899582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
    Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
    Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational design of polymer-based particulate vaccine adjuvants.
    Huete-Carrasco J; Lynch RI; Ward RW; Lavelle EC
    Eur J Immunol; 2024 Feb; 54(2):e2350512. PubMed ID: 37994660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine adjuvant formulations: a pharmaceutical perspective.
    Brito LA; Malyala P; O'Hagan DT
    Semin Immunol; 2013 Apr; 25(2):130-45. PubMed ID: 23850011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of size on particulate vaccine adjuvants.
    Shah RR; O'Hagan DT; Amiji MM; Brito LA
    Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvants in perspective.
    Vogel FR
    Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of Vaccine Adjuvants: Introduction, History, and Current Status.
    Shah RR; Hassett KJ; Brito LA
    Methods Mol Biol; 2017; 1494():1-13. PubMed ID: 27718182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in vaccine adjuvants.
    Singh M; O'Hagan D
    Nat Biotechnol; 1999 Nov; 17(11):1075-81. PubMed ID: 10545912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvants for veterinary vaccines--types and modes of action.
    Gerdts V
    Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):456-63. PubMed ID: 26697712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current adjuvants and new perspectives in vaccine formulation.
    Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A
    Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants.
    Spreafico R; Ricciardi-Castagnoli P; Mortellaro A
    Eur J Immunol; 2010 Mar; 40(3):638-42. PubMed ID: 20201020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.